Misonix Unveils New Corporate Branding and BoneScalpel® MIS Platform at 2015 North American Spine Society Annual Meeting

News provided by

Oct 14, 2015, 08:00 ET

FARMINGDALE, N.Y., Oct. 14, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery, wound and burn care, and other surgical specialties, announces the unveiling of its new Better Matters corporate branding. The company will introduce the BoneScalpel MIS Platform and several surgeon key opinion leaders ("KOLs") will present the BoneScalpel at the North American Spine Society ("NASS") annual meeting in Chicago, IL from October 14 to 17, 2015.

The Misonix team has made a significant commitment in the development of its new branding which has been specifically designed to better illustrate to all stakeholders in the patient care continuum, the company's core values and what Misonix believes to be most important. "The Better Matters brand is more than a new color, logo, or tagline; it's a culture, commitment, and promise that Misonix makes to its customers and their patients," said Scott Ludecker, Misonix Senior Vice President of Global Sales and Marketing.

"Part of being better includes the development of new platforms while continuing to innovate around those technologies where Misonix already commands a leadership position," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The BoneScalpel is a novel, ultrasonic surgical device that offers superior control in minimally-invasive spine procedures allowing for the precise removal of bone by cutting and shaping, while sparing soft tissue and neural structures. At booth #1105, the Misonix team will be introducing and demonstrating the new BoneScalpel MIS product platform giving surgeons a first-hand preview of a new product that will be released early next year. The new platform introduces the widely recognized safety and blood loss benefits of our ultrasonic technology to minimally invasive spine surgery. We look forward to meeting with many key surgeons at this meeting."

Mr. McManus continued, "To detail the benefits of the BoneScalpel in spine surgery, Misonix is working with several world-renowned spine surgeons to demonstrate the clinical and economic value that the BoneScalpel brings to the surgical suite." Misonix will be hosting several 'Meet the Expert' sessions at its booth, which will be moderated by the following leading spine surgeons:

Dr. Isador Lieberman, Texas Back Institute, Plano, TX
Dr. Juan Uribe, University of South Florida, Tampa, FL
Dr. Connor Telles, Sierra Pacific Orthopedics, Fresno, CA
Dr. Nicholas Renaldo, Orthopedic Associates of Dutchess County, Poughkeepsie, NY

Dr. Renaldo said, "At the 'Meet the Expert' sessions, spine surgeons will learn from those of us who have made BoneScalpel a go-to technology in our OR (operating room) suites about the many BoneScalpel applications along with both the clinical and economic benefits for surgeons, institutions and patients. The BoneScalpel offers controlled bone cutting, improved surgical efficiencies and soft tissue protection in spinal procedures."

The Bone Scalpel will also be presented during the NASS Solutions Showcase on Thursday, October 15 at 12:00 pm by two spine surgery thought leaders:

Ultrasonic BoneScalpel Assisted MIS TLIF
- Presented by Dr. Juan Uribe, University of South Florida, Tampa, FL
Deformity Correction with the Ultrasonic BoneScalpel
- Presented by Dr. Isador Lieberman, Texas Back Institute, Plano, TX

Dr. Lieberman commented, "The NASS Solutions Showcase is a great venue to spotlight, to a wide audience, the versatility of the BoneScalpel in spine surgery and demonstrate the benefits of controlled cutting and reduced blood loss in deformity procedures."

"The BoneScalpel MIS presentation will highlight the ultrasonic benefits the BoneScalpel offers in minimally-invasive spine procedures, like Transforaminal Lumbar Interbody Fusions," added Dr. Uribe. "In my practice, the BoneScalpel offers good visualization through a tubular retractor, controlled bone cutting, reduced bleeding and the ability to remove a large amount of viable bone graft for use later in the case. The BoneScalpel is a game changer and should be the standard of care in minimally invasive spine procedures."

Misonix looks forward to working with this outstanding group of spine surgeons in proving the value of the BoneScalpel in both open and, in the coming months, minimally invasive spine procedures.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.